Angelini Pharma acquires ThermaCare® from GSK

Rome, March 7, 2020

Angelini Pharma announces today it has acquired the ThermaCare® global business rights, excluding North America, from GSK. The deal also includes the dedicated US manufacturing site for ThermaCare in Albany, Georgia.

The acquired asset supports Angelini Pharma reinforcing both its Consumer Healthcare business and consolidating its International presence. Heat therapy is widely known to help ease muscle pain, reduce soreness, and loosen tight muscles. ThermaCare® use patented technology that produces real heat to help body rebuild damaged tissue and accelerate healing. ThermaCare® products are formulated for: Lower Back & Hip, Neck, Wrist & Shoulder, Knee & Elbow, Multi-Purpose Muscle, Multi-Purpose Joint and Menstrual.

“Along to prescription drugs, Angelini Pharma is recognized for having built a successful Consumer Healthcare business by consistently delivering high-quality solutions to our customers” said Angelini Pharma CEO Pierluigi Antonelli - “I am convinced that the ThermaCare® deal will represent a significant incremental growth engine for our accelerated international expansion”

“ThermaCare® is a global key brand, we are proud to have won an international tender” – commented Angelini Holding President Francesco Angelini and Vice Presidents Thea Paola Angelini and Sergio Marullo di Condojanni – “Thermacare is a very coveted and successful product. This acquisition confirms our engagement to strengthen the internationalization path undertaken by the Group. The operation once again points out Angelini’s commitment to supporting the development and growth of our Healthcare business”.

Angelini S.p.a.
Viale Amelia 70, 00181 Roma
P.IVA 01258691003 e C.F. Numero di iscrizione registro imprese: 03907010585
Ufficio del registro delle imprese: Roma
Capitale: € 165.000.000 I.V.

© Angelini S.p.a. - Tutti i diritti riservati